COMPARISON
Sermorelin vs Tesamorelin
3 attributes held for at least one of the two. 3 differ. Each value carries the register it came from and the date that register was read.
Answer
Sermorelin is authorised or registered in 0 and Tesamorelin in 2 of the 10 registers read. Sermorelin: No trial states a phase. Tesamorelin: No trial states a phase. 13 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Registered trials differs | 27 clinicaltrials.gov · 2026-10-03 | 24 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | Not checked no record of "fdaLabel" for sermorelin | FDA-approved: EGRIFTA SV openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Application withdrawn ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Sermorelin | placebo | Tesamorelin | placebo |
|---|---|---|---|---|
| Injection site erythema | - | - | 6.8% | 2.6% |
| Paresthesia | - | - | 2.4% | 5.0% |
| Injection site pain | - | - | 1.8% | 2.5% |
| Nephrolithiasis | - | - | 0.8% | 0.5% |
| Abdominal pain | - | - | 0.6% | 1.5% |
Trial register Sermorelin: 0 placebo-controlled trials; Tesamorelin: 4. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Sermorelin side effects · Tesamorelin side effects
LEGAL STATUS
Approval in each country read
| Country | Sermorelin | Tesamorelin | Register |
|---|---|---|---|
| United States | Not on the register | FDA-approved | Regulator FDA |
| European Union | Not on the register | Application withdrawn | Regulator EMA |
| United Kingdom | Not on the register | Not on the register | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Status unknown | TGA |
| Switzerland | Not on the register | Not on the register | Regulator Swissmedic |
| Brazil | Not on the register | Not on the register | Regulator ANVISA |
| Serbia | Not on the register | Not on the register | Regulator ALIMS |
| Singapore | Not on the register | Not on the register | Regulator HSA |
| Turkey | Not on the register | Not on the register | Regulator TITCK |
HEAD TO HEAD
13 registered trials include both
| NCT06554717 | Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV RECRUITING · updated 2026-05-19 |
|---|---|
| NCT03375788 | Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk COMPLETED · updated 2025-11-20 |
| NCT00608023 | TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy COMPLETED · updated 2022-09-30 |
| NCT02196831 | Tesamorelin Effects on Liver Fat and Histology in HIV COMPLETED · updated 2020-01-27 |
| NCT02553603 | The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment COMPLETED · updated 2019-11-04 |
| NCT00675506 | Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese COMPLETED · updated 2017-12-13 |
| NCT01263717 | Effects of Growth Hormone Releasing Hormone in HIV COMPLETED · updated 2017-10-30 |
| NCT01632592 | Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue WITHDRAWN · updated 2014-01-24 |
| NCT00795210 | Effects of Short-term Growth Hormone in HIV-infected Patients COMPLETED · updated 2014-01-08 |
| NCT00257712 | SMART: Somatotrophics, Memory, and Aging Research Trial COMPLETED · updated 2013-12-19 |
| NCT02012556 | Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients COMPLETED · updated 2013-12-16 |
| NCT00123253 | TH9507 in Patients With HIV-Associated Lipodystrophy COMPLETED · updated 2013-11-27 |
| NCT00850564 | Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men COMPLETED · updated 2011-04-19 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.